- Report
- November 2020
- 260 Pages
Global
From €2416EUR$2,750USD£2,084GBP
- Report
- November 2018
- 147 Pages
Global
From €2416EUR$2,750USD£2,084GBP
- Report
- September 2023
- 120 Pages
North America
From €5228EUR$5,950USD£4,510GBP
- Report
- May 2024
- 128 Pages
Global
From €5710EUR$6,499USD£4,926GBP
- Report
- March 2024
- 200 Pages
Global
From €3646EUR$4,150USD£3,145GBP
- Report
- February 2024
- 125 Pages
Global
From €4174EUR$4,750USD£3,600GBP
- Report
- April 2023
- 120 Pages
Global
From €4174EUR$4,750USD£3,600GBP
- Report
- January 2022
- 121 Pages
Global
From €4174EUR$4,750USD£3,600GBP
- Report
- March 2022
- 71 Pages
North America
From €1318EUR$1,500USD£1,137GBP
- Report
- May 2022
- 74 Pages
North America
From €1318EUR$1,500USD£1,137GBP
- Report
- January 2024
- 245 Pages
Global
€4389EUR$4,995USD£3,786GBP
- Training
- 60 Minutes
Global
- Report
- November 2021
- 600 Pages
Global
From €3515EUR$4,000USD£3,032GBP

The Abuse Deterrent market within the context of Analgesics is a growing sector of the pharmaceutical industry. Abuse Deterrent formulations are designed to reduce the potential for misuse and abuse of prescription medications. These formulations are designed to make the drug less attractive to abusers, such as by making it harder to crush, snort, or inject. Abuse Deterrent formulations are also designed to reduce the potential for accidental overdose.
The Abuse Deterrent market is driven by the need to reduce the misuse and abuse of prescription medications, as well as the need to reduce the potential for accidental overdose. This market is expected to continue to grow as more pharmaceutical companies develop Abuse Deterrent formulations.
Some companies in the Abuse Deterrent market include Purdue Pharma, Endo Pharmaceuticals, Teva Pharmaceuticals, and Johnson & Johnson. Show Less Read more